Taro Provides Results for September 30, 2022
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and six months ended September 30, 2022.
- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and six months ended September 30, 2022.
- Six Months ended September 30, 2022* Highlights compared to September 30, 2021
Net sales of $287.2 million increased $8.1 million. - * The September 30, 2022 results include six months results from the February 28th acquisition of Alchemee.
- The Company cautions that the foregoing 2022 financial information (including Alchemee) is unaudited and is subject to change.